Immuron Ltd Logo

Immuron Ltd

Develops oral antibodies from bovine colostrum for digestive and immune health.

IMRN | US

Overview

Corporate Details

ISIN(s):
US45254U1016 (+1 more)
LEI:
Country:
United States of America
Address:
62 LYGON STREET, 3053 CARLTON, VICTORIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of orally delivered, targeted polyclonal antibodies. The company's proprietary, patent-protected technology platform utilizes immunoglobulins (IgG) derived from hyper-immune bovine colostrum to address significant unmet medical needs. Immuron's primary focus is on gastrointestinal health, immune defense, and digestive disorders. Its portfolio of commercialized products includes Travelan®, for reducing the risk of travellers' diarrhoea; Protectyn®, for supporting gut and liver function; and ProIBS®, for the relief of symptoms related to Irritable Bowel Syndrome.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Immuron Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Immuron Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Immuron Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America OCUL
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive topical therapies for ophthalmic diseases.
United States of America OCS
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden ODI
Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea 226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway OCIN

Talk to a Data Expert

Have a question? We'll get back to you promptly.